This is a contrast between AbbVie Inc. (NYSE:ABBV) and Eli Lilly and Company (NYSE:LLY) based on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. The two companies are Drug Manufacturers Major and they also compete with each other.
Valuation and Earnings
Table 1 shows gross revenue, earnings per share and valuation of the two companies. Eli Lilly and Company is observed to has lower earnings, but higher revenue than AbbVie Inc. When business has lower price-to-earnings means it is more affordable than its counterpart presently. AbbVie Inc. is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is presently more affordable of the two stocks.
Profitability
Table 2 provides AbbVie Inc. and Eli Lilly and Companys net margins, return on equity and return on assets.
Risk and Volatility
AbbVie Inc. has a beta of 0.92 and its 8.00% less volatile than Standard & Poors 500. Competitively, Eli Lilly and Companys beta is 0.18 which is 82.00% less volatile than Standard & Poors 500.
Liquidity
The Current Ratio and a Quick Ratio of AbbVie Inc. are 1 and 0.9. Competitively, Eli Lilly and Company has 1.1 and 0.8 for Current and Quick Ratio. Eli Lilly and Companys better ability to pay short and long-term obligations than AbbVie Inc.
Analyst Recommendations
The next table highlights the given recommendations and ratings for AbbVie Inc. and Eli Lilly and Company.
AbbVie Inc.s consensus target price is $80.75, while its potential upside is 7.47%. On the other hand, Eli Lilly and Companys potential upside is 19.24% and its consensus target price is $129.33. The information presented earlier suggests that Eli Lilly and Company looks more robust than AbbVie Inc. as far as analyst view.
Insider and Institutional Ownership
Roughly 71% of AbbVie Inc. shares are owned by institutional investors while 83.7% of Eli Lilly and Company are owned by institutional investors. Insiders owned roughly 0.1% of AbbVie Inc.s shares. Competitively, Eli Lilly and Company has 12.1% of its share owned by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year AbbVie Inc.s stock price has bigger decline than Eli Lilly and Company.
Summary
On 11 of the 15 factors Eli Lilly and Company beats AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinsons disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Read more:
Reviewing AbbVie Inc. (ABBV)'s and Eli Lilly and Company (NYSE:LLY)'s results - MS Wkly
